{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:33:09Z","timestamp":1771299189053,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00228-020-03013-9","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T21:02:19Z","timestamp":1602104539000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"77","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Dosaka-Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-2950","authenticated-orcid":false,"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"3013_CR1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"key":"3013_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"key":"3013_CR3","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5:2892\u20132911","journal-title":"Am J Cancer Res"},{"key":"3013_CR4","doi-asserted-by":"publisher","first-page":"12451","DOI":"10.1038\/ncomms12451","volume":"7","author":"K Shiraishi","year":"2016","unstructured":"Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe S, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T (2016) Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun 7:12451. https:\/\/doi.org\/10.1038\/ncomms12451","journal-title":"Nat Commun"},{"key":"3013_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00280-015-2789-5","volume":"76","author":"K Kudo","year":"2015","unstructured":"Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, Iwasaku M, Kato Y, Oze I, Takigawa N, Tanimoto M, Kiura K (2015) Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemother Pharmacol 76:251\u2013256. https:\/\/doi.org\/10.1007\/s00280-015-2789-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"3013_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.lungcan.2013.05.021","volume":"81","author":"E Ichihara","year":"2013","unstructured":"Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, Hayakawa H, Minami D, Sato A, Tabata M, Tanimoto M, Kiura K (2013) Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 81:435\u2013439. https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.021","journal-title":"Lung Cancer"},{"key":"3013_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00280-014-2570-1","volume":"74","author":"S Igawa","year":"2014","unstructured":"Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Niwa H, Kusuhara S, Harada S, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N (2014) Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer Chemother Pharmacol 74:939\u2013946. https:\/\/doi.org\/10.1007\/s00280-014-2570-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3013_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-016-3232-2","volume":"79","author":"H Imai","year":"2017","unstructured":"Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M (2017) Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemother Pharmacol 79:497\u2013505. https:\/\/doi.org\/10.1007\/s00280-016-3232-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"3013_CR9","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1021\/mp400403s","volume":"10","author":"GS Smelick","year":"2013","unstructured":"Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA (2013) Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 10:4055\u20134062. https:\/\/doi.org\/10.1021\/mp400403s","journal-title":"Mol Pharm"},{"key":"3013_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/clpt.2014.87","volume":"96","author":"L Zhang","year":"2014","unstructured":"Zhang L, Wu F, Lee SC, Zhao H, Zhang L (2014) pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development. Clin Pharmacol Ther 96:266\u2013277. https:\/\/doi.org\/10.1038\/clpt.2014.87","journal-title":"Clin Pharmacol Ther"},{"key":"3013_CR11","unstructured":"European Medicines Agency. Iressa: summary of product characteristics [online]. Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001016\/WC500036358.pdf. Accessed 7 Aug 2018"},{"key":"3013_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cllc.2014.07.005","volume":"16","author":"MP Chu","year":"2015","unstructured":"Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M, Sawyer MB (2015) Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 16:33\u201339. https:\/\/doi.org\/10.1016\/j.cllc.2014.07.005","journal-title":"Clin Lung Cancer"},{"key":"3013_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cllc.2016.01.006","volume":"17","author":"Y Zenke","year":"2016","unstructured":"Zenke Y, Yoh K, Matsumoto S, Umemura S, Niho S, Ohmatsu H, Goto K, Ohe Y (2016) Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer 17:412\u2013418. https:\/\/doi.org\/10.1016\/j.cllc.2016.01.006","journal-title":"Clin Lung Cancer"},{"key":"3013_CR14","doi-asserted-by":"publisher","first-page":"85542","DOI":"10.18632\/oncotarget.13458","volume":"7","author":"NB Kumarakulasinghe","year":"2016","unstructured":"Kumarakulasinghe NB, Syn N, Soon YY, Asmat A, Zheng H, Loy EY, Pang B, Soo RA (2016) EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget 7:85542\u201385550. https:\/\/doi.org\/10.18632\/oncotarget.13458","journal-title":"Oncotarget"},{"key":"3013_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2013.06.008","volume":"82","author":"JF Hilton","year":"2013","unstructured":"Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA (2013) An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer 82:136\u2013142. https:\/\/doi.org\/10.1016\/j.lungcan.2013.06.008","journal-title":"Lung Cancer"},{"key":"3013_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","volume":"7","author":"SG Lim","year":"1993","unstructured":"Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE (1993) Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 7:317\u2013321","journal-title":"Aliment Pharmacol Ther"},{"key":"3013_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s002280050438","volume":"54","author":"S Jaruratanasirikul","year":"1998","unstructured":"Jaruratanasirikul S, Sriwiriyajan S (1998) Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 54:159\u2013161","journal-title":"Eur J Clin Pharmacol"},{"key":"3013_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/FTD.0b013e31816e2d8e","volume":"30","author":"T Uno","year":"2008","unstructured":"Uno T, Sugimoto K, Sugawara K, Tateishi T (2008) The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 30:276\u2013281. https:\/\/doi.org\/10.1097\/FTD.0b013e31816e2d8e","journal-title":"Ther Drug Monit"},{"key":"3013_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/bdd.2091","volume":"38","author":"K Narumi","year":"2017","unstructured":"Narumi K, Sato Y, Kobayashi M, Furugen A, Kasashi K, Yamada T, Teshima T, Iseki K (2017) Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. Biopharm Drug Dispos 38:501\u2013508. https:\/\/doi.org\/10.1002\/bdd.2091","journal-title":"Biopharm Drug Dispos"},{"key":"3013_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/clpt.2012.73","volume":"92","author":"NR Budha","year":"2012","unstructured":"Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92:203\u2013213. https:\/\/doi.org\/10.1038\/clpt.2012.73","journal-title":"Clin Pharmacol Ther"},{"key":"3013_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/JTO.0b013e3181e59a7b","volume":"5","author":"Y Nakamura","year":"2010","unstructured":"Nakamura Y, Sano K, Soda H, Takatani H, Fukuda M, Nagashima S, Hayashi T, Oka M, Tsukamoto K, Kohno S (2010) Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5:1404\u20131409. https:\/\/doi.org\/10.1097\/JTO.0b013e3181e59a7b","journal-title":"J Thorac Oncol"},{"key":"3013_CR22","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/j.cllc.2017.05.010","volume":"18","author":"H Yokota","year":"2017","unstructured":"Yokota H, Sato K, Okuda Y, Kobayashi H, Takeda M, Asano M, Ito H, Miura M (2017) Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer 18:e433\u2013e439. https:\/\/doi.org\/10.1016\/j.cllc.2017.05.010","journal-title":"Clin Lung Cancer"},{"key":"3013_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcph.588","volume":"56","author":"A Ruiz-Garcia","year":"2016","unstructured":"Ruiz-Garcia A, Masters JC, Mendes da Costa L, LaBadie RR, Liang Y, Ni G, Ellery CA, Boutros T, Goldberg Z, Bello CL (2016) Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol 56:223\u2013230. https:\/\/doi.org\/10.1002\/jcph.588","journal-title":"J Clin Pharmacol"},{"key":"3013_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/00498254.2016.1275880","volume":"48","author":"T Sato","year":"2018","unstructured":"Sato T, Ito H, Hirata A, Abe T, Mano N, Yamaguchi H (2018) Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica 48:73\u201378. https:\/\/doi.org\/10.1080\/00498254.2016.1275880","journal-title":"Xenobiotica"},{"key":"3013_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2165\/11587020-000000000-00000","volume":"50","author":"M Scheffler","year":"2011","unstructured":"Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 50:371\u2013403. https:\/\/doi.org\/10.2165\/11587020-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"3013_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, V\u00e1rady G, Ujhelly O, Schuetz JD, V\u00e1radi A, K\u00e9ri G, Orfi L, N\u00e9met K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485\u20131495","journal-title":"Mol Pharmacol"},{"key":"3013_CR27","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-05-2235","volume":"12","author":"M Hamilton","year":"2006","unstructured":"Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ (2006) Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12:2166\u20132171","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03013-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T01:57:45Z","timestamp":1633571865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03013-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3013"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03013-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YS, MK, YT, NS, YS, IK, KI, and MS have no conflicts of interest.HD received an honorarium from AstraZeneca for speaking at a symposium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}